| CASE REPORT |
|
| Year : 2014 | Volume
: 34
| Issue : 3 | Page : 126-128 |
|
|
Sorafenib-induced acute pancreatitis
Han-En Wang1, Chun-Ting Chen1, Hsin-Hung Huang2
1 Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
2 Department of Internal Medicine,Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
Correspondence Address:
Dr. Hsin-Hung Huang
Department of Internal Medicine, Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Gong Road, Taipei 114, Taiwan
Republic of China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1011-4564.134392
|
|
|
Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade D pancreatitis caused by sorafenib administration. Following the discontinuation of sorafenib, fasting, and fluid replacement, the patient's clinical manifestation of Grade D pancreatitis subsided in a short time. One month after discharge, she resumed sorafenib treatment (200 mg/day) due to disease progression. Based on this experience, resumption of sorafenib treatment appears to be safe. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
